Zárate A, Canales E S, Forsbach G, Fernández-Lazala R
Obstet Gynecol. 1978 Oct;52(4):442-4.
This study included a group of 50 women with amenorrhea-galactorrhea who were treated with bromocriptine (2-bromo-alpha-ergocryptine). Forty-two of these patients ovulated, and 36 conceived within 8 months of treatment. The pregnancies of 30 women reached a duration of 20 weeks or longer following ovulation induced by bromocriptine. Except in 1 case which ended in 10-week spontaneous abortion, the pregnancies of 26 patients terminated in 24 single, one twin, and one triplet births. All of the 29 newborns were healthy, and no congenital malformations were detected. The main side effects during treatment were transient constipation and nausea. Following delivery, return to pretreatment status was noted in all patients, which supports the fact that bromocriptine is not a curative agent.
本研究纳入了一组50名患有闭经-溢乳症的女性,她们接受了溴隐亭(2-溴-α-麦角隐亭)治疗。其中42名患者排卵,36名在治疗8个月内受孕。30名女性在溴隐亭诱导排卵后,孕期达到20周或更长时间。除1例在10周时自然流产外,26名患者的妊娠以24例单胎、1例双胎和1例三胎分娩告终。29名新生儿均健康,未检测到先天性畸形。治疗期间的主要副作用为短暂性便秘和恶心。分娩后,所有患者均恢复到治疗前状态,这支持了溴隐亭不是一种治愈性药物这一事实。